Wednesday, August 23, 2017

Gottlieb's First 100 Days

Over the coming days, Inside Health Policywill roll out a series of articles based on conversations with key stakeholders regarding their impressions of FDA Commissioner Scott Gottlieb’s progress thus far, and where they see him taking the agency on key issues, including: off-label promotion, regulatory reform and drug pricing. Stay tuned for in-depth coverage.

Gottlieb Issues Fewer Guidances And Delays Some Key Rules, But Hasn't Chopped Any Yet

FDA has issued fewer guidance documents and delayed some key rules during Scott Gottlieb's first 100 days as agency chief, but has yet to chop any major existing regulations despite the strong deregulatory press by a Trump White House intent on scaling back federal regulations.

Stakeholders Praise Gottlieb For Keeping The Agency On Track

Post a Comment